Andrew Combs - Mar 25, 2025 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Role
Chief Chemistry Officer
Signature
/s/ Krishna Vaddi, Attorney-in-Fact
Stock symbol
PRLD
Transactions as of
Mar 25, 2025
Transactions value $
$69,250
Form type
4
Date filed
3/27/2025, 04:40 PM
Previous filing
Feb 5, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRLD Common Stock Purchase $69.3K +100K +26.31% $0.69 480K Mar 25, 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported total includes 2,500 shares of common stock the reporting person has acquired since the date of his last ownership report through the issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c).